EODData

MEMBERSHIP REGISTER LOG IN

OTCBB, OPHLY: Ono Pharmaceutical

13 Oct 2025
LAST:

3.870

CHANGE:
 0.00		OPEN:
3.838		HIGH:
3.870		ASK:
0.000		VOLUME:
51.1K
CHG(%):
0.00		PREV:
3.870		LOW:
3.830		BID:
0.000		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
13 Oct 253.8383.8703.8303.87051.1K
10 Oct 253.8603.8703.8403.870102.2K
09 Oct 253.9703.9903.9403.950234.7K
08 Oct 253.7383.7503.7103.710124.3K
07 Oct 253.8003.8223.7903.79051.2K
06 Oct 253.8003.8103.7803.80098.3K
03 Oct 253.8003.8003.7803.800199K
02 Oct 253.7903.7903.7603.790176.8K
01 Oct 253.7883.7953.7603.790339.9K
30 Sep 253.7703.8803.7603.781358.2K

COMPANY PROFILE

Name:Ono Pharmaceutical
About:Ono Pharmaceutical Co., Ltd. produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo intravenous infusion and Kyprolis intravenous injection for malignant tumors; Emend capsule intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; Mektovi, Velexbru, and Braftovi capsules for malignant tumors; and ADLUMIZ tablets for cancer cachexia. The company also provides Glactiv tablets for type 2 diabetes; Forxiga tablets for diabetes, chronic heart failure, and chronic kidney disease; Onoact intravenous infusion for tachyarrhythmia; Opalmon tablets to treat peripheral circulatory disorder; Coralan for chronic heart failure; Orencia injections for rheumatoid arthritis; Rivastach patches for Alzheimer's disease; Ongentys tablets for Parkinson's disease; Parsabiv for the treatment of secondary hyperparathyroidism; Staybla tablets for overactive bladder; Onon capsules and Dry Syrups for bronchial asthma and allergic rhinitis; and Joyclu intra-articular injection for the improvement of joint function, as well as Recalbon tablets for osteoporosis. In addition, it develops products for hepatocellular and urothelial carcinoma; ovarian, bladder, prostate, pancreatic, gastric, esophageal, colorectal, thyroid, cell lung, and breast cancer; acute myeloid leukemia; solid tumors; myelodysplastic syndrome; melanoma; T-cell lymphoma; tachyarrhythmia; pemphigus; scleroderma; seizures; diabetic polyneuropathy; neurodegenerative diseases; autoimmune diseases; narcolepsy; and thrombosis. The company has collaborations with Adimab LLC to discover novel antibody drugs; Turbine Ltd. to identify and validate novel oncology targets; Harvard University for validating novel therapeutic targets; and Sibylla Biotech for central nervous system disorders. Ono Pharmaceutical Co., Ltd. was founded in 1717 and is headquartered in Osaka, Japan.
Sector:Healthcare
Address:8-2, Kyutaromachi 1-chome, Osaka, Japan, 541-8564
Website:https://www.ono-pharma.com
CIK:0000940821
ISIN:US6827361030
FIGI:BBG000G1Q9J1

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:15.83 
Forward P/E:13.55 
DivYield:0.05 
Div/Share:80.00 
Price to Book:1.02 
Price to Sales:0.01 
EBITDA:86.189B 
Shares:1.409B 
Market Cap:5.455B 

TECHNICAL INDICATORS

MA5:3.840.8%
MA10:3.821.4%
MA20:3.811.5%
MA50:3.811.6%
MA100:3.694.9%
MA200:3.636.5%
STO9:57.14
STO14:57.14
RSI14:55.01
WPR14:-33.33
MTM14:0.07
ROC14:0.02 
ATR:0.09 
Week High:3.993.1%
Week Low:3.714.3%
Month High:3.993.1%
Month Low:3.716.5%
Year High:4.5517.6%
Year Low:3.2120.6%
Volatility:12.29 

RECENT SPLITS

Date Ratio
04 Apr 20163-1
29 May 20145-1